Kangmei Pharmaceutical Co., Ltd. (SHA:600518)
China · Delayed Price · Currency is CNY 1.360
+0.020 (1.49%)
Aug 10, 2026, 3:00 PM CST
Kangmei Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 18,531 | 26,413 | 32,441 | 25,787 | 30,501 | 42,839 | |
Market Cap Growth | -35.58% | -18.58% | 25.81% | -15.46% | -28.80% | 221.38% |
Enterprise Value | 17,512 | 25,389 | 31,918 | 24,904 | 28,797 | 76,028 |
Last Close Price | 1.34 | 1.91 | 2.34 | 1.86 | 2.20 | 3.09 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | 2557.44 | 3783.85 | 251.53 | - | 5.41 |
Forward PE | - | 2.56 | 2.56 | 2.56 | 2.56 | 2.56 |
PS Ratio | 3.68 | 5.03 | 6.25 | 5.29 | 7.30 | 10.32 |
PB Ratio | 2.54 | 3.61 | 4.50 | 3.64 | 4.37 | 4.30 |
P/TBV Ratio | 2.71 | 3.86 | 4.87 | 4.00 | 4.83 | 4.64 |
P/FCF Ratio | - | - | - | - | - | 1006.12 |
P/OCF Ratio | 117.30 | 237.22 | - | - | - | 199.99 |
PEG Ratio | - | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.48 | 4.83 | 6.15 | 5.11 | 6.89 | 18.31 |
EV/EBITDA Ratio | - | 493.17 | - | 52.89 | - | - |
EV/EBIT Ratio | - | - | - | 138.67 | - | - |
EV/FCF Ratio | - | - | - | - | - | 1785.59 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.03 | 0.02 | 0.04 | 0.04 | 0.02 |
Debt / EBITDA Ratio | 3.41 | 2.17 | - | 0.49 | - | - |
Debt / FCF Ratio | - | - | - | - | - | 4.82 |
Net Debt / Equity Ratio | -0.14 | -0.14 | -0.12 | -0.11 | -0.18 | -0.22 |
Net Debt / EBITDA Ratio | -59.84 | -20.51 | 6.64 | -1.70 | 1.70 | 0.89 |
Net Debt / FCF Ratio | 15.63 | 9.99 | 1.71 | 1.92 | 1.56 | -51.99 |
Asset Turnover | 0.37 | 0.39 | 0.37 | 0.33 | 0.27 | 0.17 |
Inventory Turnover | 1.67 | 1.81 | 1.76 | 1.54 | 1.26 | 0.91 |
Quick Ratio | 0.77 | 0.81 | 0.71 | 0.66 | 0.82 | 1.00 |
Current Ratio | 1.26 | 1.26 | 1.17 | 1.12 | 1.36 | 1.68 |
Return on Equity (ROE) | -0.17% | 0.17% | 0.17% | 1.47% | -31.78% | - |
Return on Assets (ROA) | -1.17% | -1.03% | -1.84% | 0.76% | -4.17% | -7.71% |
Return on Invested Capital (ROIC) | 3.07% | -1.01% | -2.28% | 2.80% | -15.42% | -33.25% |
Return on Capital Employed (ROCE) | -3.20% | -2.80% | -5.20% | 2.20% | -10.70% | -27.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.08% | 0.04% | 0.03% | 0.40% | -8.81% | 18.48% |
FCF Yield | -0.36% | -0.40% | -1.51% | -1.62% | -2.62% | 0.10% |
Payout Ratio | - | - | - | - | - | 0.17% |
Buyback Yield / Dilution | -15.27% | -3.25% | -39.38% | 27.54% | -1.85% | -0.55% |
Total Shareholder Return | -15.27% | -3.25% | -39.38% | 27.54% | -1.85% | -0.55% |